Skip to main content
O

Optellum

Optellum develops AI-based decision support software that utilizes imaging biomarkers to enhance the early detection of lung cancer. This technology enables clinicians to identify at-risk patients and optimize their management strategies, improving patient outcomes in lung health care.

Oxford, United KingdomFounded 2016495K+ followers
Updated 20 months ago

Funding

$25.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

MF
Funding rounds are not available yet.

Founders

Product

Problem

Lung cancer is a leading cause of cancer deaths, and early detection is critical for improving patient outcomes. However, identifying at-risk patients and making optimal management decisions based on traditional imaging techniques can be challenging. This can lead to delays in diagnosis and treatment, potentially reducing the chances of successful intervention.

Solution

Optellum has developed a lung precision care platform that leverages AI-driven clinical decision support to enhance the early diagnosis and management of lung cancer. The platform analyzes CT scans using advanced machine learning algorithms to identify and track at-risk patients, enabling clinicians to make more informed decisions. By integrating with existing clinical workflows, Optellum aims to improve the efficiency and accuracy of lung cancer diagnosis, ultimately leading to better patient care and outcomes.

Target Audience

The primary target audience includes pulmonologists, radiologists, oncologists, and other healthcare providers involved in lung cancer screening, diagnosis, and treatment, as well as hospitals and healthcare systems.

Features

  • AI-powered analysis of CT scans to identify suspicious lung nodules
  • Risk scoring and prediction models to stratify patients based on their likelihood of developing lung cancer
  • Virtual Nodule Clinic (VNC) for managing incidentally detected lung nodules
  • Integration with hospital systems and clinical workflows
  • Tools for monitoring nodule growth and progression over time
  • Support for multimodal therapy decisions
  • ISO 27001:2022 certification for data security and compliance
This profile is AI-generated and may contain inaccuracies.